JP5270684B2 - 脂肪肝疾患用のバイオマーカー及びその使用方法 - Google Patents

脂肪肝疾患用のバイオマーカー及びその使用方法 Download PDF

Info

Publication number
JP5270684B2
JP5270684B2 JP2010532284A JP2010532284A JP5270684B2 JP 5270684 B2 JP5270684 B2 JP 5270684B2 JP 2010532284 A JP2010532284 A JP 2010532284A JP 2010532284 A JP2010532284 A JP 2010532284A JP 5270684 B2 JP5270684 B2 JP 5270684B2
Authority
JP
Japan
Prior art keywords
biomarkers
steatohepatitis
level
subject
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010532284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503547A5 (enExample
JP2011503547A (ja
Inventor
クリーディー、ブルース、ジェイ．、ジュニア マク
バーガー、アルヴィン
フー、ユンフ
カルハン、サティシュ、シー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of JP2011503547A publication Critical patent/JP2011503547A/ja
Publication of JP2011503547A5 publication Critical patent/JP2011503547A5/ja
Application granted granted Critical
Publication of JP5270684B2 publication Critical patent/JP5270684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/16—Phosphorus containing
    • Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2010532284A 2007-11-02 2008-10-31 脂肪肝疾患用のバイオマーカー及びその使用方法 Active JP5270684B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98494207P 2007-11-02 2007-11-02
US60/984,942 2007-11-02
US4245908P 2008-04-04 2008-04-04
US61/042,459 2008-04-04
PCT/US2008/082013 WO2009059150A2 (en) 2007-11-02 2008-10-31 Biomarkers for fatty liver disease and methods using the same

Publications (3)

Publication Number Publication Date
JP2011503547A JP2011503547A (ja) 2011-01-27
JP2011503547A5 JP2011503547A5 (enExample) 2011-12-08
JP5270684B2 true JP5270684B2 (ja) 2013-08-21

Family

ID=40591773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532284A Active JP5270684B2 (ja) 2007-11-02 2008-10-31 脂肪肝疾患用のバイオマーカー及びその使用方法

Country Status (5)

Country Link
US (3) US20100279956A1 (enExample)
EP (3) EP2930512B1 (enExample)
JP (1) JP5270684B2 (enExample)
ES (1) ES2402142T3 (enExample)
WO (1) WO2009059150A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172775A4 (en) * 2007-06-25 2010-12-01 Ajinomoto Kk METHOD OF EVALUATING VISCERAL GREASE ACCUMULATION
EP2930512B1 (en) * 2007-11-02 2018-01-31 Metabolon, Inc. Biomarkers for fatty liver disease and methods using the same
CN102105792A (zh) 2008-05-28 2011-06-22 巴斯夫欧洲公司 评估肝毒性的工具和方法
WO2009153131A1 (en) * 2008-05-28 2009-12-23 Basf Se Means and methods for assessing liver enzyme induction
JP5676275B2 (ja) * 2008-12-24 2015-02-25 学校法人慶應義塾 酸化ストレス検出用マーカー、肝臓疾患マーカー及び医薬品の検定方法
US9051614B2 (en) * 2009-09-11 2015-06-09 The Chinese University Of Hong Kong Methods for assessing liver pathologies
JP2011232164A (ja) * 2010-04-27 2011-11-17 Keio Gijuku 肝臓疾患マーカー、その測定方法、装置及び医薬品の検定方法
EP3273247A1 (en) * 2010-06-10 2018-01-24 Metanomics Health GmbH Methods for the diagnosis of liver diseases
WO2011158590A1 (ja) * 2010-06-18 2011-12-22 学校法人 慶應義塾 肝臓疾患マーカー、その測定方法、装置及び医薬品の検定方法
US8728824B2 (en) 2011-06-22 2014-05-20 Quest Diagnostics Investments Inc. Mass spectrometric determination of fatty acids
JP6260275B2 (ja) * 2011-06-30 2018-01-17 味の素株式会社 脂肪肝の評価方法、脂肪肝評価装置、脂肪肝評価方法、脂肪肝評価プログラム、脂肪肝評価システム、および端末装置
CA2885416A1 (en) 2012-09-21 2014-03-27 The Governing Council Of The University Of Toronto Cmpf as a biomarker for diabetes and associated methods
CN107076753B (zh) * 2014-09-30 2019-01-18 深圳华大基因科技有限公司 肥胖人群特异性生物标志组合物及其用途
WO2016081534A1 (en) * 2014-11-19 2016-05-26 Metabolon, Inc. Biomarkers for fatty liver disease and methods using the same
RU2617236C1 (ru) * 2015-12-02 2017-04-24 государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ определения целесообразности проведения иммунологического обследования у пациентов неалкогольной жировой болезнью печени
WO2017184586A1 (en) 2016-04-18 2017-10-26 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
CN115236166A (zh) 2016-05-29 2022-10-25 深圳市绘云生物科技有限公司 肝病相关生物标志物和其使用方法
EP3502703A1 (en) 2017-12-22 2019-06-26 Metanomics Health GmbH Method for the assessment of nafld
CN109060977B (zh) * 2018-07-13 2024-07-02 深圳市绘云生物科技有限公司 用于肝纤维化和肝硬化诊断的生物标志物和试剂盒及使用方法
US11693005B2 (en) 2018-08-07 2023-07-04 Florida Atlantic University Board Of Trustees Methods for identifying treatments that reduce the actions of substances of abuse and addiction
WO2020066162A1 (ja) * 2018-09-26 2020-04-02 株式会社島津製作所 非アルコール性脂肪肝疾患の検出方法、非アルコール性脂肪肝疾患検出用キットおよび非アルコール性脂肪肝疾患検出用バイオマーカー
US20200241005A1 (en) * 2019-01-25 2020-07-30 Viscient Biosciences, Inc. Compositions and methods for the diagnosis and treatment of diseases of the liver
WO2021226042A1 (en) * 2020-05-04 2021-11-11 University Of Florida Research Foundation, Incorporated Biomarkers for assessing liver disease
US12100484B2 (en) 2021-11-01 2024-09-24 Matterworks Inc Methods and compositions for analyte quantification
US11754536B2 (en) 2021-11-01 2023-09-12 Matterworks Inc Methods and compositions for analyte quantification
CN116165385B (zh) * 2023-04-25 2023-07-18 南方医科大学南方医院 用于肝癌诊断的血清代谢标志物及其筛选方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61260896A (ja) * 1985-05-15 1986-11-19 Sekisui Chem Co Ltd 胆汁酸の分析方法
WO1996037777A1 (en) * 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
WO2001078652A2 (en) 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
CN1636058B (zh) * 2001-05-14 2011-06-08 龚大为 新型丙氨酸转氨酶及其应用方法
JP2003139753A (ja) * 2001-11-02 2003-05-14 Mitsubishi Pharma Corp 胆汁酸１８成分の一斉分析法
ES2226549B1 (es) * 2002-12-18 2006-07-16 One Way Liver Genomics, S.L. Metodo para el diagnostico de esteatohepatitis no alcoholica (nash) mediante el empleo de marcadores moleculares.
US20040121305A1 (en) * 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
US7452678B2 (en) * 2003-06-24 2008-11-18 Bristol-Myers Squibb Company Identification of biomarkers for liver toxicity
CA2546601A1 (en) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7078064B2 (en) * 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
EP1739431A4 (en) * 2004-04-23 2008-10-15 Ajinomoto Kk METHOD FOR ASSESSING NON-ALCOHOLIC STEATOHEPATITIS
EP1619257A1 (en) * 2004-07-23 2006-01-25 One Way Liver Genomics, S.L. Method for the in vitro diagnosis of non-alcoholic steatohepatitis
US20060160237A1 (en) * 2004-12-06 2006-07-20 Applera Corporation Method of screening urine for organic acids
US7860656B2 (en) * 2005-02-03 2010-12-28 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of hepatic steatosis using biochemical markers
US20070004045A1 (en) * 2005-06-07 2007-01-04 Xia Xu Analysis of large numbers of estrogens and other steroids and applications thereof
US7972785B2 (en) * 2006-01-24 2011-07-05 Industrial Technology Research Institute (Itri) Biomarkers for liver fibrotic injury
JP5227168B2 (ja) 2006-03-29 2013-07-03 ヤマサ醤油株式会社 肝障害の検出方法、判定方法及び予測方法
US20090111122A1 (en) * 2006-04-06 2009-04-30 Eisai R&D Management Co., Ltd. METHOD FOR NON-INVASIVE EXAMINATION OF NON-ALCOHOLIC STEATOHEPATITIS BY QUANTIFICATION OF CYTOCHROME-c, AND TEST KIT
WO2007136674A1 (en) 2006-05-19 2007-11-29 The Cleveland Clinic Foundation Detection and monitoring of liver damage
EP3285072B1 (en) * 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
US20090075284A1 (en) * 2006-09-19 2009-03-19 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
EP2133692B1 (en) * 2006-11-06 2013-10-09 Yokohama City University Diagnosis method for fatty liver disease, diagnosis apparatus, diagnosis program, diagnostic agent, and method for screening for therapeutic agent for fatty liver disease
WO2008156662A1 (en) * 2007-06-14 2008-12-24 George Mason Intellectual Properties, Inc. Methods of diagnosing non-alcoholic steatohepatitis (nash)
BRPI0815095B1 (pt) * 2007-07-17 2021-04-13 Metabolon, Inc Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo
EP2930512B1 (en) * 2007-11-02 2018-01-31 Metabolon, Inc. Biomarkers for fatty liver disease and methods using the same
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same

Also Published As

Publication number Publication date
WO2009059150A3 (en) 2009-06-18
EP2546649B1 (en) 2015-02-25
EP2930512B1 (en) 2018-01-31
US20100279956A1 (en) 2010-11-04
HK1216189A1 (en) 2016-10-21
EP2930512A2 (en) 2015-10-14
EP2227689A4 (en) 2011-03-30
US20190120855A1 (en) 2019-04-25
EP2227689B1 (en) 2012-12-26
EP2930512A3 (en) 2015-12-02
US20150377910A1 (en) 2015-12-31
US9977034B2 (en) 2018-05-22
EP2546649A3 (en) 2013-03-27
EP2227689A2 (en) 2010-09-15
WO2009059150A2 (en) 2009-05-07
ES2402142T3 (es) 2013-04-29
EP2546649A2 (en) 2013-01-16
JP2011503547A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
JP5270684B2 (ja) 脂肪肝疾患用のバイオマーカー及びその使用方法
US10823744B2 (en) Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
CN104204798A (zh) 膀胱癌的生物标志物和使用所述生物标志物的方法
CN107002113A (zh) 脂肪肝病的生物标志物和其使用方法
CN106461685B (zh) 神经酰胺及其在诊断cvd中的应用
WO2010045180A1 (en) Biomarkers for inflammatory bowel disease and methods using the same
WO2008036691A2 (en) Biomarkers for prostate cancer and methods using the same
JP2016520192A (ja) 腎機能に関連付けられるバイオマーカーおよびそれを使用する方法
WO2009014639A2 (en) Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same
EP2951313A1 (en) Biomarkers related to insulin resistance progression and methods using the same
JP2013532830A (ja) 前立腺癌に関するバイオマーカー及びそれを使用する方法
WO2007134028A2 (en) Biomarkers for depression and methods using the same
WO2009026153A1 (en) Biomarkers for alzheimer's disease and methods using the same
CN103814295B (zh) 用于评估肾毒性的手段和方法
WO2019097089A1 (en) Methods for prediction and early detection of diabetes
KR20230113742A (ko) 난소암의 검출 및 치료를 위한 방법
JP2020064055A (ja) 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
TWI735470B (zh) 糖尿病性腎病之判定方法、及於此種判定方法中生物標記之用途
WO2022248363A1 (en) Use of soluble trem2 as a non-invasive biomarker for non-alcoholic steatohepatitis (nash)
JP7239139B2 (ja) 肝硬変の診断方法、非アルコール性脂肪肝炎及び肝細胞がんの合併症の診断方法並びに非アルコール性脂肪肝炎及び食道胃静脈瘤の合併症の診断方法
Băluţă et al. Exploring the role of metabolomics in kidney transplantation: a systematic review of the literature
CN119510604A (zh) 预测aclf患者会否死亡的生物标志物、系统及其应用
HK1216189B (en) Biomarkers for fatty liver disease and methods using the same
Kiranmayi et al. Metabolomics-the new “omics” of health care
Merchant et al. Urinary proteomics and candidate biomarker discovery for diabetic nephropathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130417

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130509

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5270684

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250